


STATUS OF THE CLAIMS

1-40. (cancelled).

41. (previously presented) A compound having Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

R₁ is C₁₋₂ alkyl or C₁₋₂ haloalkyl;

R₂ is branched or unbranched alkyl or cycloalkyl or substituted or unsubstituted aryl, alkylaryl, heteroaryl, or alkylheteroaryl;


X is CONH;


Y₁ is (CH₂)₁₋₅, wherein one or more carbon can be replaced by one or more heteroatoms selected from oxygen, sulfur, and nitrogen, and one or more hydrogens in CH₂ groups can be replaced by a branched or unbranched alkyl or cyclic alkyl or substituted or unsubstituted aryl, alkylaryl, heteroaryl, or alkylheteroaryl;


Y₂ is (CH₂)₁₋₅, wherein one or more carbon can be replaced by one or more heteroatoms selected from oxygen, sulfur, and nitrogen, and one or more hydrogens in CH₂ groups can be replaced by a branched or unbranched alkyl or cyclic alkyl or substituted or unsubstituted aryl, alkylaryl, heteroaryl, or alkylheteroaryl; and





Z is CONH.

42. (currently amended) The compound of claim 1, wherein said compound is selected from the group consisting of:




















, and















43. (previously presented) A pharmaceutical composition comprising a compound of claim 41 and a pharmaceutically acceptable carrier.

44. (currently amended) The pharmaceutical composition of claim 43, wherein said compound is selected from the group consisting of:














, and



—, and



- 9 -